What Should You Think of the New Abbott Labs?

The new year has come, and Abbott Labs' (ABT +0.08%) spinoff of its branded pharmaceuticals division into the new company AbbVie (ABBV +0.36%) is complete. AbbVie is getting all of the attention from analysts at the moment because of its powerhouse arthritis drug, Humira, which generates the bulk of the revenue for the company -- but what about Abbott Labs? In this video, Motley Fool health care bureau chief Brenton Flynn tells us what he thinks of the trimmer new Abbott sans the branded pharmaceuticals, and why it reminds him a lot of Johnson & Johnson (JNJ +0.65%).